The Institute for Clinical and Economic Review revised its cost effectiveness estimates for Allergan PLC’s new oral CGRP receptor antagonist drug for acute migraine after the company re-analyzed data demonstrating the drug's effectiveness when some patients had to wait beyond two hours to feel the benefit.
The revisions were discussed at a meeting of ICER’s Midwestern Comparative Effectiveness Public Advisory Council on 23 January.